Xilio Therapeutics Inc (XLO)
1.07
+0.14
(+15.04%)
USD |
NASDAQ |
May 31, 16:00
1.06
-0.01
(-0.93%)
After-Hours: 20:00
Xilio Therapeutics Enterprise Value: 5.516M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 5.516M |
| May 30, 2024 | 0.3522M |
| May 29, 2024 | 0.57M |
| May 28, 2024 | -0.1203M |
| May 24, 2024 | 4.778M |
| May 23, 2024 | 5.516M |
| May 22, 2024 | 8.469M |
| May 21, 2024 | 10.31M |
| May 20, 2024 | 12.16M |
| May 17, 2024 | 8.100M |
| May 16, 2024 | 5.885M |
| May 15, 2024 | 7.362M |
| May 14, 2024 | 6.254M |
| May 13, 2024 | 7.362M |
| May 10, 2024 | 9.577M |
| May 09, 2024 | 12.53M |
| May 08, 2024 | 10.68M |
| May 07, 2024 | 12.53M |
| May 06, 2024 | 12.16M |
| May 03, 2024 | 9.576M |
| May 02, 2024 | 4.778M |
| May 01, 2024 | 5.885M |
| April 30, 2024 | 4.409M |
| April 29, 2024 | 4.409M |
| April 26, 2024 | 6.254M |
| Date | Value |
|---|---|
| April 25, 2024 | 3.301M |
| April 24, 2024 | 5.147M |
| April 23, 2024 | 4.778M |
| April 22, 2024 | 6.623M |
| April 19, 2024 | 8.469M |
| April 18, 2024 | 13.27M |
| April 17, 2024 | 11.42M |
| April 16, 2024 | 14.01M |
| April 15, 2024 | 12.53M |
| April 12, 2024 | 9.576M |
| April 11, 2024 | 12.90M |
| April 10, 2024 | 10.14M |
| April 09, 2024 | 11.18M |
| April 08, 2024 | 16.69M |
| April 05, 2024 | 7.387M |
| April 04, 2024 | 7.732M |
| April 03, 2024 | 10.83M |
| April 02, 2024 | 17.04M |
| April 01, 2024 | 18.76M |
| March 28, 2024 | -4.158M |
| March 27, 2024 | -23.74M |
| March 26, 2024 | -23.18M |
| March 25, 2024 | -22.06M |
| March 22, 2024 | -21.86M |
| March 21, 2024 | -21.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-110.14M
Minimum
Jun 17 2022
598.63M
Maximum
Nov 16 2021
15.29M
Average
-11.27M
Median
Feb 03 2023
Enterprise Value Benchmarks
| Gilead Sciences Inc | 100.46B |
| FibroGen Inc | 56.95M |
| Avalo Therapeutics Inc | -86.37M |
| IGM Biosciences Inc | 197.90M |
| AEON Biopharma Inc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.20M |
| Total Expenses (Quarterly) | 16.54M |
| EPS Diluted (Quarterly) | -0.62 |
| Earnings Yield | -240.2% |